Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $3.55
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 30, 26 |
Daily · Wilder smoothing
| Needham |
| maintain |
| Buy |
| Buy |
| Apr 8, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Mar 18, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Mar 18, 26 | Needham | maintain | Buy | Buy |
| Mar 18, 26 | Citizens | maintain | Market Outperform | Market Outperform |
| Mar 18, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 31, 25 | RBC Capital | downgrade | Outperform | Sector Perform |
| Oct 31, 25 | Citizens | maintain | Market Outperform | Market Outperform |
| Aug 12, 25 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.68 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 30.96 | Oscillator | Neutral |
| Williams %R (14) | -77.42 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.07 (Hist 0.00) | Oscillator | Buy |
| Average Directional Index (14) | 12.62 (+DI 17.0 / -DI 22.5) | Trend | Neutral |
| EMA 20 | 3.66 | MA | Sell |
| SMA 20 | 3.66 | MA | Sell |
| EMA 50 | 3.81 | MA | Strong Sell |
| SMA 50 | 3.86 | MA | Strong Sell |
| SMA 200 | 4.64 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Perry Jennifer Scott | officer: Chief Operating Officer | S-Sale | 30 @ $3.57 | $107 |
| Oct 5, 26 | Perry Jennifer Scott | officer: Chief Operating Officer | S-Sale | 326 @ $3.78 | $1.23K |
| Oct 2, 26 | Swanton Robert Charles | director | S-Sale | 3,431 @ $3.47 | $11.91K |
| Oct 2, 26 | Skynner Michael | officer: CHIEF SCIENTIFIC OFFICER | S-Sale | 1,942 @ $3.47 | $6.74K |
| Oct 5, 26 | Skynner Michael | officer: CHIEF SCIENTIFIC OFFICER | S-Sale | 503 @ $3.57 | $1.80K |
| Oct 2, 26 | Hannay Michael Charles Ferguson | officer: CHIEF PROD & SUPPLY CHAIN OFF | S-Sale | 1,572 @ $3.47 | $5.45K |
| Oct 5, 26 | Hannay Michael Charles Ferguson | officer: CHIEF PROD & SUPPLY CHAIN OFF | S-Sale | 242 @ $3.57 | $864 |
| Oct 2, 26 | Perry Jennifer Scott | officer: Chief Operating Officer | S-Sale | 1,094 @ $3.47 | $3.80K |
Stock news · updated daily
Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent
Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 86.2% of Bicycle
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “We are pleased with the progress we made during the second quarter. Our financial discipline with refined focus on nuzefatide pevedotin and our nex.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -0.56 | -0.72 | Miss -27.6% | $629.0K |
| Apr 30, 2026 | -0.52 | -0.87 | Miss -67.3% | $887.0K |
| Mar 17, 2026 | -0.94 | -0.29 | Beat 69.1% | $47.95M |
| Oct 30, 2025 | -1.09 | -0.85 | Beat 22.0% | $11.73M |
| Aug 8, 2025 | -0.95 | -1.14 | Miss -20.0% | $2.92M |
| May 1, 2025 | -0.86 | -0.88 | Miss -2.3% | $9.98M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4/A | Oct 7, 2026 | 2026-10-07 18:24:47 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:45:16 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:45:14 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:45:11 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:45:09 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:45:06 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:34:56 | View |
| 3/A | Oct 6, 2026 | 2026-10-06 16:33:43 | View |
| 8-K | Aug 20, 2026 | 2026-08-20 16:05:23 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 10:02:35 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BCYC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.3x | -8.2x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.5x | EPS est. -2.43 | In line |
| Price / Book | 0.5x | 2.2x | Discount |
| Price / Sales | 4.0x | 49.0x | Discount |
| EV / EBITDA | 1.4x | -4.6x | Discount |
| Return on equity | -33.2% | — | Weak |
| Gross margin | 100.0% | -114.1% | Below hist. |
| Debt / Equity | 0.03 | 0.09 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -0.68 | Distress |
Discounted cash flow model